Phil Ambery

Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

Hiddo J.L. Heerspink, Arihiro Kiyosue, David C. Wheeler et al. · The Lancet · 2023 · 126 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐na <i>ï</i> ve type 2 diabetes mellitus patients

João Borges, John P. Bilezikian, Angela R. Jones-Leone et al. · Diabetes Obesity and Metabolism · 2011 · 90 citations

Medicine, Endocrinology, Pharmacology +17

Efficacy and safety of low‐dose otelixizumab anti‐<scp>CD</scp>3 monoclonal antibody in preserving C‐peptide secretion in adolescent type 1 diabetes: <scp>DEFEND</scp>‐2, a randomized, placebo‐controlled, double‐blind, multi‐centre study

Phil Ambery, Tom Donner, N. Biswas et al. · Diabetic Medicine · 2013 · 86 citations

Medicine, Endocrinology, Pharmacology +10

40th EASD Annual Meeting of the European Association for the Study of Diabetes

M. Veitenhansl, K. Stegner, F. X. Hierl et al. · Diabetologia · 2004 · 68 citations · Full text

Medicine, Endocrinology, Diabetology +11

Specific associations of insulin resistance with impaired health-related quality of life in the Hertfordshire Cohort Study

Wolff Schlotz, Phil Ambery, Holly Syddall et al. · Quality of Life Research · 2006 · 43 citations

Medicine, Endocrinology, Epidemiologic Methods +13